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OBJECTIVES We sought evidence of a change in the prevalence of atrial fibrillation (AF) over a 30-year
period among residents of Rochester, Minnesota.
BACKGROUND Atrial fibrillation is increasingly encountered in clinical practice, but there is limited data on
secular trends of AF over time.
METHODS Within a longitudinal case-control study of ischemic stroke, the prevalence of AF and of
selected comorbid conditions among incident stroke cases and age- and gender-matched
controls between 1960 and 1989 was determined.
RESULTS The mean age  standard deviation for the 1,871 stroke cases (45% men) and matched
controls was 75  11 years. For cases, age-adjusted estimates of AF prevalence for 1960 to
1969, 1970 to 1979, and 1980 to 1989 were 11%, 13%, and 16%, respectively, for men, and
13%, 16%, and 20% for women. For controls, the rates were 5%, 8%, and 12%, respectively,
for men, and 4%, 6%, and 8% for women. Increasing AF prevalence was associated with
increasing age (doubling of odds per decade of age in both cases and controls) and calendar
time adjusted for age and gender (cases: odds ratio [OR] per 5 years 1.13, 95% confidence
interval [CI], 1.05 to 1.22; controls: OR per 5 years 1.24, 95% CI 1.12 to 1.37). The rates
of increase with calendar time were significant for cases (p  0.001) and controls (p  0.001)
and comparable between the genders.
CONCLUSIONS The prevalence of AF increased significantly in ischemic stroke patients and their controls
from 1960 to 1989 in Rochester, Minnesota, independent of age and gender. The rate of
increase did not differ significantly between men and women. (J Am Coll Cardiol 2003;42:
93–100) © 2003 by the American College of Cardiology Foundation
Atrial fibrillation (AF) is a growing epidemic (1). Approx-
imately 2.3 million individuals in the U.S. currently carry
this diagnosis (2), and it is projected that 5.6 million
Americans will have AF by 2050. Aside from being an
independent predictor of mortality (3), AF is also a cause of
substantial morbidity, including stroke (4–7), and has a
major impact on health care costs (5).
See page 101
Atrial fibrillation is strongly associated with age (5), and
this, in combination with a burgeoning older population,
provides the basis for the developing epidemic. The Fra-
mingham investigators identified a significant increase in
the prevalence of AF in men, but not in women, over the
period 1968 to 1989, even after adjusting for age and
comorbid conditions (8). To our knowledge, there have
been no other published studies on trends of AF over time.
We conducted an analysis of data collected in a longitudinal,
population-based study of ischemic stroke in the commu-
nity of Rochester, Minnesota, to determine whether the
prevalence of AF changed among patients with incident
ischemic stroke and among age- and gender-matched con-
trol subjects over a 30-year period (1960 to 1989).
METHODS
The study received review and approval of ethics by the
Institutional Review Board of the Mayo Foundation. The
community of Rochester, Minnesota, is well suited to
population-based studies because of a number of unique
features. Geographically, the community is relatively iso-
lated from other urban centers, and medical care is delivered
by only a few health care providers. These include the Mayo
Clinic and its two affiliated hospitals, which provide primary
through tertiary care services in all specialties and subspe-
cialties, the Olmsted Medical Center and its affiliated
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hospital, and a small number of private practitioners. The
majority of care is provided by the Mayo Clinic, which, for
more than 80 years, has maintained a unified medical record
containing details of all inpatient and outpatient encounters,
laboratory reports, and patient-related correspondence for
each registered patient. Within each medical record, diag-
noses made during office visits, clinic consultations, emer-
gency room visits, hospital admissions, nursing home care,
and autopsy examinations, as well as surgical procedures, are
listed on a master sheet and subsequently coded. Coded
diagnoses are then transferred to a central diagnostic index.
This diagnostic index allows all patients with a diagnosis of
interest to be readily identified. The resources of the
Rochester Epidemiology Project (9) also include an estab-
lished medical linkage system, which allows access to
medical information on patients seen in practices in the
surrounding communities. Thus, all patients in the commu-
nity with a particular disease or diagnosis can be readily
identified (10).
With the use of the resources of the Rochester Epidemi-
ology Project and those of the Mayo Stroke Center (11), a
case-control study of the incidence of ischemic stroke in the
Rochester community was previously conducted (11,12).
The definitions of ischemic stroke and methods for selecting
control subjects have been reported (11,13). Briefly, a pool
of potential age- (within 2 years) and gender-matched
control subjects from the general Rochester population were
identified using the medical records of the Rochester Epi-
demiology Project (9,11). Potential control subjects in-
cluded persons without any documented history of ischemic
stroke and with a health care contact within 1 year of the
diagnosis of the relevant stroke case, as demonstrated by a
recorded blood pressure measurement. The date of blood
pressure assessment became the reference date for the
control subject. Control subjects also had to have been
residents of Rochester for at least one year before the
reference date. The first control subject was defined as the
person from the pool of potential controls whose registra-
tion number was the closest to that of the case, thus
ensuring more comparable duration of medical records. If
the first eligible control subject failed any validation checks,
another potential control subject with the next closest
registration number would be selected.
Within the framework of the case-control study of
incident ischemic stroke in Rochester, Minnesota (11,12),
we determined the prevalence of a history of AF (hereafter
referred to as “prevalence of AF”) and selected comorbid
conditions as of the date of stroke diagnosis for case patients
and reference date for control subjects. Clinical data for each
study subject were abstracted from the entire medical record
by a trained nurse abstractor supervised by a physician.
References to possible AF in the clinical record had to be
substantiated by an electrocardiogram (ECG) documenting
at least one episode of the arrhythmia in order for a
diagnosis of AF to be coded. For purposes of this analysis,
no distinction was made between lone, intermittent/
paroxysmal, chronic/persistent, or valvular/nonvalvular AF.
Atrial flutter alone, without any intervening episodes of AF,
was not included in this definition. Cases in which AF was
first detected at the time of stroke diagnosis were not
included in prevalence calculations, as it would not be
possible to determine whether the arrhythmia preceded or
followed the onset of stroke. For comparability, AF initially
detected on the reference date of control subjects was not
used in prevalence calculations.
Standard definitions of comorbid conditions (see July 2
issue online for Appendix at www.cardiosource.com/
jacc.html) were applied over the entire period, as previously
reported (12). Comorbid conditions were coded as present
or absent and the date of first mention recorded, allowing
prevalence calculations for each of the three decades (1960
to 1969, 1970 to 1979, 1980 to 1989) to be performed.
However, the precise time order of these conditions was
unavailable, precluding analysis of temporal relationships
between comorbid conditions and AF. The use of ECG and
echocardiography within 30 days of stroke/reference date
was available from the original case-control study and
provided a crude estimate of the influence of rates of
utilization of these diagnostic modalities on ascertainment
of AF and comorbid conditions for the study period.
Statistical analyses. Logistic regression models (14) were
used to assess the effects of age, gender, and calendar time
on the odds of a history of AF and of each comorbid
condition separately among case patients and control sub-
jects. Age (both linear and quadratic), gender, and their
interactions were also considered. Then, calendar year, both
as a continuous and as a discrete (by decade) variable, was
assessed, adjusting for best-fit age and gender models.
Interactions of calendar year with age and gender were
considered. Only those significant interactions with calen-
dar year that affected the qualitative interpretation were
reported. Once the best logistic model was determined for
each condition, the proportions of case patients and control
subjects with each condition (adjusted for the demographic
variables in the model) were estimated by use of the logit
function (14). In order to summarize the age-adjusted
results, prevalence estimates derived from the multivariate
models are reported for age 75 years, because this was the
mean age for the cohort (median age 76 years). Model-
based prevalence estimates of AF for other ages were also
provided in a table for men and women with and without
ischemic stroke. For all model building, two-sided p values
were used and a variable was considered statistically signif-
icant only if p  0.05.
Abbreviations and Acronyms
AF  atrial fibrillation
CI  confidence interval
ECG  electrocardiogram/electrocardiographic
OR  odds ratio
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RESULTS
Prevalence of AF: effects of age, gender, and calendar
time. A total of 3,742 residents of Rochester, mean age 75
 11 years (median age 76 years, range 45 to 105 years),
were included in the study. The age and gender distribution,
stratified by ischemic stroke status, is shown in Table 1. Of
1,871 Rochester residents (838 men, 1,033 women) who
had a confirmed ischemic stroke between 1960 and 1989,
327 (105 men, 222 women), or 17%, had a history of AF
before the date of stroke diagnosis (Table 2). Among the
1,871 age- and gender-matched control subjects, 176 (9.4%)
had a history of AF (72 men, 104 women) prior to the
reference date. The observed prevalence of AF among case
patients and control subjects, stratified by age, gender, and
calendar decade is outlined in Figure 1.
In the stroke patients, there was a significant increase in
the prevalence of AF with increasing age (odds ratio [OR]
per 10 years of age 1.81, 95% confidence interval [CI] 1.58
to 2.07; p  0.001), but there was no significant difference
between the genders. After adjustment for age and gender,
there was a significant calendar-time effect: the OR per five
years was 1.13 (95% CI 1.05 to 1.22, p  0.001). This
change in the prevalence of AF over calendar time did not
vary according to gender (p  0.702) or age (p  0.349)
(Fig. 2). In this multivariate model, the age-adjusted esti-
mates of prevalence for the three decades (1960 to 1969,
1970 to 1979, 1980 to 1989) were 11%, 13%, and 16%,
respectively, for men and 13%, 16%, and 20% percent for
women.
In the control subjects, there was also a significant
increase in the prevalence of AF with advancing age
(OR per 10 years 2.22, 95% CI 1.84 to 2.68), and male
gender was associated with a greater likelihood of AF
(OR 1.50, 95% CI 1.06 to 2.11). After adjustment for age
and gender, there was also a significant calendar-time effect:
the OR per five years was 1.24 (95% CI 1.12 to 1.37, p 
0.001). This change in the prevalence of AF over calendar
time also did not vary according to gender (p  0.098) or
age (p  0.617) (Fig. 2). In this multivariate model, the
age-adjusted estimates of prevalence for the three decades
(1960 to 1969, 1970 to 1979, 1980 to 1989) were 5%, 8%,
and 12%, respectively, for men and 4%, 6%, and 8% for
women.
Over the 30-year period, age-adjusted prevalence of AF
increased significantly (p  0.001) for the total cohort of
3,742 individuals (Fig. 2). The rates of increase were
significant for both case patients (p  0.001) and control
subjects (p  0.001) but did not differ between the two
groups (p  0.154) and did not differ between the two
genders within groups (p  0.702 for cases, p  0.098 for
controls). Although the main analyses of the overall trends
of prevalence of AF were based on age-adjusted prevalence
values for age 75 years (the mean age for both cases and
controls), the modeled prevalence estimates of AF for men
and women of various ages with and without ischemic
stroke also showed trends of progressive increase over the
three decades (Table 3).
Time trends of comorbid conditions. From 1960 to 1989,
significant increases in prevalent hypertension, coronary
Table 1. Age and Gender Distribution for Ischemic Stroke Cases and Control Subjects
Age (yrs)
Total45–54 55–64 65–74 75–84 85–94 >95
Ischemic stroke cases
Male, n (% of cases) 55 (2.9) 164 (8.8) 292 (15.6) 260 (13.9) 60 (3.2) 7 (0.5) 838 (45)
Female, n (% of cases) 30 (1.6) 92 (4.9) 228 (12.2) 408 (21.8) 243 (13) 32 (1.7) 1033 (55)
Matched controls
Male, n (% of controls) 54 (2.9) 164 (8.8) 288 (15.4) 258 (13.8) 67 (3.6) 7 (0.5) 838 (45)
Female, n (% of controls) 27 (1.4) 94 (5.0) 225 (12.0) 409 (21.9) 250 (13.4) 28 (1.5) 1033 (55)
Table 2. Observed Prevalence (%) of Atrial Fibrillation Among Rochester Residents, Stratified by Gender, Age, Presence or Absence
of Ischemic Stroke, and Decade
Ischemic Stroke Cases Control Subjects
1960–1969 1970–1979 1980–1989 1960–1969 1970–1979 1980–1989
Gender and age No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Men and women, all ages 57 (11) 93 (17) 177 (22) 23 (5) 45 (8) 108 (13)
Men 21 (8) 34 (14) 50 (15) 11 (4) 18 (7) 43 (13)
Age 65 yrs 3 (4) 5 (8) 5 (7) 0 (0) 0 (0) 1 (1)
Age 65–84 yrs 14 (8) 23 (14) 33 (15) 9 (5) 14 (9) 35 (16)
Age 85 yrs 4 (24) 6 (33) 12 (38) 2 (11) 4 (18) 7 (21)
Women 36 (15) 59 (19) 127 (26) 12 (5) 27 (9) 65 (13)
Age 65 yrs 6 (17) 3 (8) 6 (12) 0 (0) 0 (0) 0 (0)
Age 65–84 yrs 24 (15) 39 (18) 50 (19) 7 (4) 20 (9) 25 (10)
Age 85 yrs 6 (14) 17 (31) 71 (40) 5 (11) 7 (13) 40 (22)
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artery disease, and valvular heart disease were evident in
both cases and controls. Prevalent myocardial infarction was
found to increase significantly in cases and older controls,
whereas prevalent congestive heart failure, diabetes mellitus,
and history of cardiac surgery increased significantly only in
the cases (Table 4, Fig. 3).
Use of ECG and echocardiography. For both ischemic
stroke cases and their controls, there was an increase in the
use of ECG within the 30-day window of the stroke/
reference date from the first decade studied to the second,
but no further increase was evident thereafter (Table 5). The
overall rates of utilization of ECG were higher in the cases,
but the trends over time appeared similar for both cases and
controls. The utilization of echocardiography increased
substantially over the three decades. It was 0%, 5%, and 53%
for the stroke cases, and 0%, 2%, and 18% for the controls,
for 1960 to 1969, 1970 to 1979, and 1980 to 1989,
respectively.
Figure 1. Prevalence of atrial fibrillation in 1,871 patients with ischemic stroke and their age- and gender-matched controls, stratified by age, gender, and
calendar decade.
Figure 2. Trends for age-adjusted prevalence of atrial fibrillation in 1,871 patients with ischemic stroke and their age- and gender-matched controls,
stratified by gender. *Significant (p  0.001) time trend among case patients; insignificant (p  0.702) difference between men and women. †Significant
(p  0.001) time trend among controls; insignificant (p  0.098) difference between men and women.
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DISCUSSION
Prevalence of AF and factors contributing to develop-
ment of an epidemic. This study evaluated the prevalence
rates of AF in patients with incident stroke and in age- and
gender-matched controls over a 30-year period. Although
the observed and the modeled prevalence rates should not be
assumed to be identical to the actual prevalence of AF in the
general population of Rochester, Minnesota, the secular
trends of AF prevalence observed for these unique groups
are informative of the epidemiology of this arrhythmia over
the time period examined. Consistent with other studies
(15–19), age is a potent risk factor for the development of
AF: each decade of age was associated with a doubling of
the odds for AF (controls: OR 2.22, 95% CI 1.84 to 2.86;
cases: OR 1.81, 95% CI 1.58 to 2.07). This fact, coupled
with the steadily increasing numbers of persons reaching
very old age, most certainly contributes to the growing
epidemic of AF.
Second, a “calendar-time effect” on the prevalence of AF,
independent of age, was evident. The age-adjusted preva-
lence estimates were those of the predicted prevalence from
the multivariate models for age 75 years, which was the
mean age for the cohort. Over the 30-year period, the
age-adjusted prevalence of AF increased significantly (p 
0.001) for the total cohort of 3,742 individuals (Fig. 2). The
rates of increase were significant for both case patients (p 
0.001) and control subjects (p  0.001) but did not differ
between the two groups (p  0.154). In contrast to the
findings from the Framingham cohort, this effect did not
differ significantly by gender. Within case and control
groups, the rates of increase over time were significant for
both men and women but did not differ between the two
genders (p  0.702 for cases, p  0.098 for controls).
Third, the precise contribution of ascertainment bias to
the observed changes in prevalence of AF in the study
population could not be readily determined; however, these
changes were unlikely to be largely accounted for by the
utilization pattern of ECG. Relative to 1960 to 1969, the
frequency with which ECG was performed within30 days
of the stroke/reference date was somewhat higher in 1970 to
1979: cases had an increase of 12%, and controls an increase
of 9% (Table 5). Yet the increase in observed AF prevalence
was 6% in cases and 3% in controls (Table 2). Further, there
was no increase in the utilization of ECG for either the
cases or the controls from the second to the third decade
(Table 5). Yet the observed increase in prevalence of AF for
both cases and controls was 5% (Table 2). While acknowl-
edging the limitation of assessing utilization of ECG within
Table 3. Modeled Prevalence (%) of Atrial Fibrillation Among Rochester Residents, Stratified
by Gender, Age, Presence or Absence of Ischemic Stroke, and Decade
Gender and
Age (yrs)
Ischemic Stroke Cases Control Subjects
1960–1969
%
1970–1979
%
1980–1989
%
1960–1969
%
1970–1979
%
1980–1989
%
Men
Age 45 1.96 2.48 3.15 0.52 0.79 1.21
Age 55 3.48 4.40 5.55 1.15 1.74 2.64
Age 65 6.11 7.67 9.59 2.51 3.79 5.69
Age 75 10.52 13.04 16.07 5.41 8.05 11.82
Age 85 17.51 21.32 25.69 11.26 16.27 22.93
Age 95 27.71 32.85 38.44 21.99 30.15 39.80
Women
Age 45 2.51 3.18 4.02 0.35 0.53 0.81
Age 55 4.44 6.27 7.03 0.77 1.17 1.78
Age 65 7.73 10.78 12.02 1.69 2.57 3.88
Age 75 13.15 17.92 19.78 3.68 5.53 8.23
Age 85 21.47 28.27 30.81 7.83 11.51 16.60
Age 95 33.05 41.58 44.57 15.87 22.41 30.66
Table 4. Change in Prevalence (Odds Ratio) for Five-Year
Changes in Calendar Time for Various Comorbid Conditions
Group Condition
Odds Ratio
(95% CI)
Ischemic stroke cases
Atrial fibrillation 1.13 (1.05–122)
Hypertension 1.09 (1.02–1.15)
Coronary artery disease 1.10 (1.04–1.17)
MI 1.11 (1.03–1.19)
CHF 1.17 (1.08–1.26)
Diabetes mellitus 1.19 (1.10–1.28)
Valvular heart disease 1.25 (1.13–1.38)
Cardiovascular surgery 2.16 (1.69–2.76)
Control subjects
Atrial fibrillation 1.24 (1.12–1.37)
Hypertension 1.10 (1.05–1.17)
Coronary artery disease 1.08 (1.01–1.17)
MI, at age 65 yrs 0.90 (0.77–1.04)
MI, at age 75 yrs 1.06 (0.97–1.16)
MI, at age 85 yrs 1.26 (1.11–1.43)
CHF, at age 65 yrs 0.87 (0.70–1.07)
CHF, at age 75 yrs 0.98 (0.86–1.11)
CHF, at age 85 yrs 1.10 (0.98–1.23)
Diabetes mellitus 0.99 (0.89–1.09)
Valvular heart disease 1.56 (1.35–1.88)
Cardiovascular surgery 1.45 (0.90–2.32)
CHF  congestive heart failure; CI  confidence interval; MI  myocardial
infarction.
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30 days of the stroke/reference date, to attribute the
change in prevalence to the degree of increased utilization of
ECG suggested by these data requires an implausibly high
rate of AF among the additional subjects having an ECG in
later time periods.
The rates of utilization of ECG were higher in cases than
in controls for all three decades, although the trends over
time were similar. The higher utilization rate in the cases
probably reflected the greater cardiovascular disease burden
in these subjects, and therefore more frequent indication for
ECG assessment. For symptomatic AF, both cases and
controls should have had similar likelihood of receiving
ECG assessment, and detection rate should be comparable.
A systematic under-detection of silent AF in the controls
remains possible, because these individuals were less disease
burdened and, therefore, possibly less likely to undergo
ECG assessment as part of evaluation for other conditions
they might have had.
Changes over time in the prevalence of comorbid condi-
tions, however, may play an important role in the genesis
and propagation of this epidemic (Fig. 3). The risk of AF
development is a function not only of advancing age but also
of the total disease burden and the presence among those
who survive to older ages of specific comorbid conditions
that are themselves risk factors for AF. However, the precise
effect of changes in the prevalence of comorbid conditions
on the secular trends of AF could not be readily determined
in this study.
The role of comorbid conditions in the epidemic of
AF. Hypertension, coronary artery disease, diabetes melli-
tus, and heart failure are among the age-related comorbid
conditions that likely play a central role in the propagation
of the AF epidemic. In addition to increasingly greater
numbers of persons reaching the age at which the risk of AF
escalates, a significant proportion of the elderly population
have survived these conditions (20–31), which in them-
selves are risk factors for the development of AF. Diastolic
dysfunction, which occurs commonly in patients with these
conditions, was recently identified as a robust predictor of
nonvalvular AF and may serve as the common pathophys-
iologic link between these conditions and AF development
(32). There was also evidence of an increase in prevalence of
valvular heart disease over time, both for cases and for
controls. This could in part be related to an increase in
detection rate as a result of greater sophistication and
utilization of echocardiography, although an actual increase
in the number of older individuals who have developed
degenerative valve disease could also have contributed (33).
Variations in the prevalence of AF in the U.S. In this
study, the age-adjusted prevalence rates of AF among
Figure 3. Prevalence of atrial fibrillation (AF) and comorbid conditions in 1,871 patients with ischemic stroke and their age- and gender-matched controls,
stratified by calendar decade. CAD  coronary artery disease; CHF  congestive heart failure; CS  cardiac surgery; DM  diabetes mellitus; HTN 
hypertension; MI  myocardial infarction; VHD  valvular heart disease.
Table 5. Use of Electrocardiography Within 30 Days of Stroke
in Case Patients or Reference Date in Control Subjects for
Three Decades
1960–1969 1970–1979 1980–1989
No. (%) No. (%) No. (%)
Ischemic stroke cases
No ECG 127 (25) 70 (13) 121 (15)
ECG 375 (75) 479 (87) 699 (85)
Control subjects
No ECG 295 (59) 273 (50) 438 (54)
ECG 208 (41) 278 (50) 379 (46)
ECG  electrocardiogram.
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Rochester men in the control group were 5% for the period
1960 to 1969 and 12% for the period 1980 to 1989. The
age-adjusted prevalence rates were 3.2% for 1968 to 1970
and 9.1% for 1987 to 1989 for men in the Framingham
study (8). In the Cardiovascular Health Study, the preva-
lence of AF was 6.2% for men, all of whom were 65 years of
age or older (15). The differences in the prevalence rates
could be related to the differences in study criteria, methods
of ascertainment, and techniques of age adjustment for
estimation of the prevalence rates, although true variations
in the geographic distribution of AF cannot be excluded.
Study limitations. Rochester is predominantly a white
community, and the extent to which the findings of this
study may be generalized to the population at large is
unknown. We acknowledge that the prevalence of AF in
neither the stroke cases nor the controls is necessarily
representative of the prevalence rate of AF in the general
Rochester community. This notwithstanding, the trends of
AF identified in this study remain informative with respect
to the changes in prevalence of AF over the 30-year period
in men and women who had an ischemic stroke and in age-
and gender-matched controls. The precise contribution of
ascertainment bias on the overall change in AF prevalence
could not be readily determined. Also, AF first detected on
stroke/reference date was not counted as part of the “prev-
alence of history of AF,” and, therefore, the true prevalence
of AF in both stroke cases and control subjects could have
been underestimated.
Although we evaluated concurrent trends in prevalence
for a number of important comorbid conditions, we did not
assess other putative risk factors such as alcohol consump-
tion, sleep apnea, thyroid disorders, infection, or pulmonary
disease, which could also have affected the trends in AF.
The reasons for the observed trends in AF prevalence are
undoubtedly multifactorial, and the impact of each contrib-
uting factor could not be readily addressed in this study.
Clinical implications. Analyzing multiple concurrent
trends is a highly complex process, and cause-and-effect
interpretations are not possible. Nevertheless, simple de-
scriptive analyses of secular trends, such as those reported
here, are vital benchmarks for our health care efforts. The
data from this study contributes to the understanding of the
epidemiology and magnitude of AF as a public health
problem. The projected 2.5-fold increase in the number of
patients with AF over the next 50 years, based on cross-
sectional census data (2), may potentially underestimate the
magnitude of the problem as it evolves over time.
Conclusions. The prevalence of AF increased significantly
over the three decades from 1960 to 1989 in Rochester
residents who had ischemic stroke and in their age- and
gender-matched controls. The magnitude of increase did
not differ significantly between men and women. A con-
comitant increase in the prevalence of certain comorbid
conditions might have contributed in part to the identified
trends in AF. The observations are alarming with poten-
tially far-reaching consequences not only in terms of the
growing AF burden, but also its impact on stroke, the
quality of life in many elderly, and the attendant socioeco-
nomic implications. Aggressive AF risk reduction and
management are pivotal to the containment of this epi-
demic. Studies are needed to advance our understanding of
the forces shaping this epidemic, to quantify the impact of
AF on resource utilization and health outcomes, and to
determine effective primary prevention strategies for the
control and mitigation of the effects of this arrhythmia.
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APPENDIX
Myocardial infarction was based on three criteria: clinical
history indicative of acute ischemia; presence of serial ECG
changes indicative of myocardial damage; and diagnostic
increase in serum creatinine phosphokinase (introduced in
1963), lactic dehydrogenase (introduced in 1963), and
serum glutamic-oxaloacetic transaminase (introduced in
1955).
Coronary heart disease was defined by presence of angina
or myocardial infarction.
Hypertension was considered present if the subject was
given antihypertensive treatment and/or if a systolic blood
pressure 160 mm Hg or a diastolic blood pressure 95
mm Hg on two or more measurements occurred before the
stroke or reference date. An increased pressure occurring in
the context of an acute illness or injury was considered an
exception.
Congestive heart failure was defined by the presence of at
least four of the following 11 criteria: dyspnea on ordinary
exertion, paroxysmal nocturnal dyspnea, acute pulmonary
edema, distended neck veins, bilateral ankle edema (not due
to a condition other than cardiac failure), hepatomegaly (not
due to liver disease), rales in the absence of pulmonary
disease, presence of third heart sound or summation gallop,
radiographic evidence of pulmonary congestion (pleural
fluid, pulmonary venous congestion, prominent pulmonary
veins) with or without cardiomegaly, circulation time 24 s
(arm to tongue), pulmonary edema, visceral congestion, and
cardiomegaly at autopsy.
Valvular heart disease was defined by clinical diagnosis
with or without ancillary evidence on chest radiography and
echocardiography.
Diabetes mellitus was considered present if the National
Diabetes Data Group criteria were met before the date of
stroke or reference date.
Atrial fibrillation was considered present only if there was
ECG confirmation.
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